ACICLOVIR AGILA, ACICLOVIR ALPHAPHARM, ACICLOVIR MYLAN (Alphapharm Pty Ltd)
Product name
ACICLOVIR AGILA, ACICLOVIR ALPHAPHARM, ACICLOVIR MYLAN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
150 (255 working days)
Active ingredients
aciclovir sodium
Registration type
New generic medicine
Indication
ACICLOVIR AGILA, ACICLOVIR ALPHAPHARM, ACICLOVIR MYLAN (powder for injection) is indicated for:
- Promoting resolution of acute clinical manifestations of mucocutaneous Herpes simplex virus infections in immunocompromised patients
- Treatment of severe first episode primary or non-primary genital herpes in immune competent patients
- Treatment of acute manifestations of Varicella zoster virus infection in immunocompromised patients
- Treatment of Herpes zoster (shingles) in immune competent patients who show very severe acute local or systemic manifestations of the disease. (Benefits can be expected in patients with rash duration shorter than 72 hours. The use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles)
- Treatment of Herpes simplex encephalitis